The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.

Plain-language guide to PMID 32932174 (2020): randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, fatty liver & elevated liver enzymes.

Key Facts

PMID: 32932174
Journal: Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
Year: 2020
Study type: Randomized Controlled Trial
Authors: Fathi M et al. (4 authors)
DOI: 10.1016/j.jtemb.2020.126635

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of fatty liver & elevated liver enzymes.

Evidence indicates the positive effects of zinc on insulin resistance and oxidative stress in metabolic syndrome or diabetes.

Non-alcoholic fatty liver disease (NAFLD) is the main hepatic manifestation of insulin resistance and metabolic syndrome.

Who Took Part

Serum levels of zinc, homeostasis model of assessment-estimated insulin resistance (HOMA-IR), lipid profile, serum superoxide dismutas1 (SOD1) and malondialdhyde (MDA) levels were assessed.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The present study is the first clinical trial that evaluated the effects of zinc supplementation on metabolic and oxidative stress status in overweight/obese patients with NAFLD undergoing calorie- restriction diet.

Topics PubMed links to this paper include Insulin, Malondialdehyde, Non-alcoholic Fatty Liver Disease, Obesity, Overweight, Oxidative Stress and Superoxide Dismutase.

Author keywords: Calorie- restriction diet, Insulin resistance and Zinc supplementation.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with fatty liver & elevated liver enzymes.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Fatty liver & elevated liver enzymes research.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.